Literature DB >> 26509014

P16 and HPV discordance in metastatic carcinoma of cervical lymph nodes of unknown primary.

Alyssa Ralph1, Andrew Meyer2, Ronald Sirota3, Arthur Hooberman2.   

Abstract

The prognostic utility of HPV in oropharyngeal squamous cell carcinoma (OPSCC) and non-OPSCC as has been well documented. Currently, a standardized IHC scoring system does not exist and is needed to define HPV positivity. We have recently seen a patient that provides a caution in using p16 status as a diagnostic aid.

Entities:  

Keywords:  HPV; Oropharyngeal squamous cell carcinoma; P16; Unknown primary

Year:  2015        PMID: 26509014      PMCID: PMC4614647          DOI: 10.1002/ccr3.338

Source DB:  PubMed          Journal:  Clin Case Rep        ISSN: 2050-0904


Case

A 44-year-old nonsmoking male presented with a tender neck mass of several weeks duration. CT Neck revealed two enlarged right cervical lymph nodes. Flexible laryngoscopy revealed no obvious primary. A fine needle aspiration of the neck mass was felt to be most consistent with squamous cell carcinoma. PET/CT revealed three FDG-avid lymph nodes in the right neck and no evidence of distant metastases. He underwent a right selective neck dissection with bilateral tonsillectomies and directed biopsies of the nasopharynx, base of the tongue, and pyriform sinuses. Pathology revealed no evidence of a primary tumor, and eight of 10 right cervical lymph nodes positive for poorly differentiated carcinoma most consistent with squamous cell carcinoma. The tumor was strongly positive for p16 on IHC staining, supporting the diagnosis of a squamous cell carcinoma of the head and neck region with unknown primary site. He was treated with a conventional 7-week course of concomitant cisplatin and radiation therapy. Post treatment PET/CT revealed recurrence in a single cervical lymph node and new hepatic metastases. Biopsy of the hepatic metastasis revealed mucoepidermoid carcinoma similar in morphology to the prior biopsy specimens. IHC was positive for p16. PCR testing was performed on both the original lymph node specimen and the liver metastasis; both were negative for HPV.

Discussion

P16, a cyclin-dependent kinase inhibitor, activates the cyclin D1 CKD4 and 6 complex, which prevents phosphorylation of the retinoblastoma protein (pRb) and leads to cell cycle arrest 1,2. Overexpression of p16 has been demonstrated in a wide range of human malignancies 3. HPV infection can lead to overexpression of p16 by virally-expressed oncoprotein E7 binding to and inactivating pRb, thus leading to overexpression of p16 1,2. In this case, the expression of p16 in the setting of a metastatic carcinoma to cervical lymph nodes with squamous differentiation was taken as supporting evidence of an unknown primary squamous cell carcinoma of the head and neck region. The subsequent biopsy revealed mucoepidermoid salivary gland carcinoma, which has been shown to overexpress p16 in the absence of HPV infection 4–12. Thus, it is important to recognize that although IHC staining for p16 is a useful surrogate for HPV infection, discordance both due to testing inaccuracy as well as true p16 positivity without HPV infection exists and should be considered when evaluating a carcinoma originating in the head and neck region 1,4–15,17–20.

Conflict of Interest

None declared.
  20 in total

1.  p16 positive oropharyngeal squamous cell carcinoma:an entity with a favorable prognosis regardless of tumor HPV status.

Authors:  James S Lewis; Wade L Thorstad; Rebecca D Chernock; Bruce H Haughey; James H Yip; Qin Zhang; Samir K El-Mofty
Journal:  Am J Surg Pathol       Date:  2010-08       Impact factor: 6.394

2.  p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma.

Authors:  Christine H Chung; Qiang Zhang; Christina S Kong; Jonathan Harris; Elana J Fertig; Paul M Harari; Dian Wang; Kevin P Redmond; George Shenouda; Andy Trotti; David Raben; Maura L Gillison; Richard C Jordan; Quynh-Thu Le
Journal:  J Clin Oncol       Date:  2014-09-29       Impact factor: 44.544

3.  Comparison of human papillomavirus in situ hybridization and p16 immunohistochemistry in the detection of human papillomavirus-associated head and neck cancer based on a prospective clinical experience.

Authors:  Aatur D Singhi; William H Westra
Journal:  Cancer       Date:  2010-05-01       Impact factor: 6.860

4.  The relationship between p16 expression and high-risk human papillomavirus infection in squamous cell carcinomas from sites other than uterine cervix: a study of 137 cases.

Authors:  Erika E Doxtader; Anna-Luise A Katzenstein
Journal:  Hum Pathol       Date:  2011-08-12       Impact factor: 3.466

5.  Relation between human papillomavirus positivity and p16 expression in head and neck carcinomas--a tissue microarray study.

Authors:  Frank König; Gisbert Krekeler; Johannes F Hönig; Carlos Cordon-Cardo; Gösta Fischer; Monika Korabiowska
Journal:  Anticancer Res       Date:  2007 Jan-Feb       Impact factor: 2.480

Review 6.  Cellular senescence and tumor suppressor gene p16.

Authors:  Hani Rayess; Marilene B Wang; Eri S Srivatsan
Journal:  Int J Cancer       Date:  2011-12-05       Impact factor: 7.396

7.  Deregulated expression of p16INK4a and p53 pathway members in benign and malignant myoepithelial tumours of the salivary glands.

Authors:  H Vékony; K Röser; T Löning; F M Raaphorst; C R Leemans; I Van der Waal; E Bloemena
Journal:  Histopathology       Date:  2008-12       Impact factor: 5.087

8.  Differential expression of p16(INK4A) and cyclin D1 in benign and malignant salivary gland tumors: a study of 44 Cases.

Authors:  G Jour; K West; V Ghali; D Shank; G Ephrem; B M Wenig
Journal:  Head Neck Pathol       Date:  2013-01-13

9.  Human papillomaviruses are not involved in the etiopathogenesis of salivary gland tumors.

Authors:  Alena Skálová; Jana Kašpírková; Pavel Andrle; Lubor Hostička; Tomáš Vaneček
Journal:  Cesk Patol       Date:  2013-04

10.  Detection of human papillomavirus in cervical lymph nodes: a highly effective strategy for localizing site of tumor origin.

Authors:  Shahnaz Begum; Maura L Gillison; M Ali Ansari-Lari; Keerti Shah; William H Westra
Journal:  Clin Cancer Res       Date:  2003-12-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.